Management of upper respiratory tract infections in children by Cotton, MF et al.
CPD Article
SA Fam Pract 2008                  Vol 50 No 26
Management of upper 
respiratory tract infections in children
Cotton MF, MMed, PhD, DTM&H, Cert(ID) 
Innes S, MBBCh, MRCPCH 
Jaspan H, MD, PhD 
Madide A, FCPaed(SA) 
Rabie H, FCPaed(SA)
Paediatric Infectious Diseases Unit, Department of Paediatrics and Child Health, Stellenbosch University
Correspondence to: Prof Mark Cotton, e-mail: mcot@sun.ac.za
Abstract
Upper respiratory tract infection (URTI) occurs commonly in both children and adults and is a major cause of mild morbidity. It has a 
high cost to society, being responsible for absenteeism from school and work and unnecessary medical care, and is occasionally 
associated with serious sequelae. URTIs are usually caused by several families of virus; these are the rhinovirus, coronavirus, 
parainfluenza, respiratory syncytial virus (RSV), adenovirus, human metapneumovirus, influenza, enterovirus and the recently 
discovered bocavirus. This review will mainly focus on the rhinovirus, where significant advances have been made in understanding 
the epidemiology, natural history and relationship with other pathogens. 
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Introduction
Upper respiratory tract infection (URTI) or “the common cold” is a 
symptom complex usually caused by several families of virus; these 
are the rhinovirus, coronavirus, parainfluenza, respiratory syncytial 
virus (RSV), adenovirus, human metapneumovirus and influenza. 
Occasionally the enterovirus is implicated in summer. Recently, the 
newly discovered bocavirus (related to the parvovirus) has also 
been linked to URTI.1 The term “URTI” is probably a misnomer as it 
incorrectly implies an absence of lower respiratory tract symptoms. 
URTI occurs commonly in both children and adults and is a major 
cause of mild morbidity. URTIs have a high cost to society, being 
responsible for missed work and unnecessary medical care. 
Occasionally they have serious sequelae. Often regarded as trivial, 
URTIs do not receive serious attention in medical school curricula. 
Bacterial complications such as otitis media and acute sinusitis and 
inflammatory sequelae such as asthma, however, are well described. 
Readers are referred to a recent review of symptomatic management 
of URTI in children in this journal.2 This review will mainly focus 
on the rhinovirus, where significant advances have been made in 
understanding the epidemiology, natural history and relationship with 
other pathogens. Where relevant, features specific to other causes 
of URTI will be mentioned. By understanding the natural history, 
spectrum of complications and awareness of “warning signs”, the 
family practitioner may be better equipped to manage the most 
common human viral infection. Management issues include the correct 
use of antibiotics, new information warning against over the counter 
medication for URTI in children under two years of age, emerging data 
on complementary and alternate medications (CAM) and other low-
cost evidence-based interventions. 
 
Epidemiology of URTI
In industrial United States of America (USA), adults have two to four, 
and children have between six and eight URTIs a year.3,4 There is little 
data from developing countries. In a cross-sectional study from rural 
Uganda where data was collected from 300 women with children under 
two years of age, 37% of children had a current URTI.5 
Recent studies from Kenya in the rural Kilifi district on RSV 
epidemiology in a birth cohort demonstrated that almost 70% of RSV 
infections were of the upper respiratory tract only with no seasonality.6
The majority of infections are spread through contact with infected 
secretions and can be interrupted through hand hygiene. Rhinoviral 
infections occur throughout the year, most commonly in spring and 
autumn. Influenza peaks in winter have been noted universally.7–9 
Rhinovirus
Virology 
The rhinovirus, a single-stranded RNA virus, has more than 100 
antigenic types and is the most common cause of URTIs in adults and 
children. As the rhinovirus grows best in tissue culture at 33 oC, it was 
believed earlier that it would not infect the lower airways. However, it 
was recently found to replicate in the lower respiratory tract.10 
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Symptoms and signs
The symptoms and signs of the common cold have been well 
delineated in adult natural history studies since the 1960s.11 Onset is 
heralded by nasal stuffiness and throat irritation, usually accompanied 
by low-grade fever, anorexia and myalgia. Sneezing is accompanied 
by a watery nasal discharge, which after one to three days becomes 
mucopurulent and can persist for up to ten days in over a third of 
patients. Coughing occurs commonly probably due to inflammation 
of the lower respiratory tract (Figure 1). Rhinovirus infection causes 
concomitant inflammation of the paranasal sinuses.12
Figure 1: Natural history and symptoms of rhinovirus infection 
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Still reporting 





20% by day 10
70%
> 40% through day 9
Table I: Comparison of signs and symptoms in adults and children11,13
The natural history of URTI in children has been less well defined 
because of reliance on parent recall or physician referral. As the 
rhinovirus is difficult to culture, only with the advent of sensitive and 
specific reverse transcriptase polymerase chain reaction techniques 
has the natural history been better documented. The first major 
community-based natural history study in children was published in 
2008. Pappas and colleagues conducted a survey in Virginia, USA.13 
Children between five and ten years of age were enrolled and data 
was collected on 81 cases from the onset of symptoms through day 
ten. Rhinoviruses were responsible for 37 (almost 50%) of cases.
The most common signs were coughing and sneezing and the most 
common symptoms were congestion and a runny nose. These signs 
and symptoms persisted for the first week. Coughing was present in 
46% at onset, peaking at 69% on day one and still present in ≥ 50% 
at day seven. Rhinorrhoea occurred in 71% on day one and was still 
present in ≥ 50% by day five. Sneezing occurred in 36% at onset, 
peaking at 55% on day one and still noted in 35% by day five. Fever 
was uncommon, reported in only 15% on day one and declining even 
further. Headache was reported in 15% on day one and declined 
thereafter. Vomiting and diarrhoea were extremely uncommon. None of 
the children received antibiotics. A comparison between the course of 
URTI in children and adults is shown in Table I.11,13
Important management points from natural history data are that 
coughing is extremely common in children and adults and can persist 
with high frequency until day nine. In contrast, fever is uncommon 
especially after the first day, and its presence suggests either another 
cause such as influenza and/or a bacterial complication such as otitis 
media or sinusitis.
 
Lower respiratory disease associated with the rhinovirus
Two studies of hospitalised children have recently documented 
considerable lower respiratory disease caused by the rhinovirus. In 
the USA, the rhinovirus was implicated in 26% of children younger 
than five years of age hospitalised for acute respiratory disease.14 
The rhinovirus was detected more frequently than RSV, the virus 
traditionally linked to most lower airway morbidity and was highly 
associated with a history of asthma. In 
infants under six months of age, apnoea was 
common (7 out of 62). In a similar study from 
Spain in children under two years of age, 
the rhinovirus was associated with 25% of 
admissions for respiratory disease.15 Diagnoses 
included recurrent wheezing, bronchiolitis 
and pneumonia. Sixty per cent of children 
were febrile. Multiple viruses were isolated in 
almost 40% of children, suggesting a role for 




The main emphasis of management is symptom relief of fever, 
nasal congestion and coughing. A variety of adrenergic agonist, 
anticholinergic, antihistamine preparations, antitussives and 
expectorants are marketed for these purposes. Common constituents 
of such medication include first generation antihistamines, 
antipyretics (paracetamol) or anti-inflammatory agents (ibuprofen), 
cough suppressants such as dextromethorphan, expectorants 
(guaifenesin) and decongestants such as pseudoephedrine and 
phenylpropanolamine.16 
Although they provide symptom relief, there is no conclusive evidence 
that they shorten the duration of symptoms.17,18 Recently, the Food 
and Drug Administration issued an advisory statement warning against 
using over the counter medications for URTIs in children under two 
years of age.19 This arose from a report of three infants under six 
months of age who died after receiving these medications, possibly 
linked to the pseudoephedrine component. Since there is no proven 
benefit over placebo of these medications in children of any age, and 
the risks of side effects in children are great, practitioners should be 
cautious in recommending or prescribing such therapies.
Antibiotics
Antibiotic use in childhood URTIs remains contentious since more 
than 90% of the infections are of viral aetiology. The reasons cited for 
prescribing antibiotics include diagnostic uncertainty, socio-cultural and 
economic pressures, concern over malpractice litigation and parental 
expectations of an antibiotic.20 Antibiotics are overprescribed for URTIs 
and promote antibiotic resistance.21 However, there is a role for defined 
indications, such as severe acute rhinosinusitis lasting more than ten 
days and severe acute otitis media.22
Fahey et al’s quantitative systematic review of randomised controlled 
trials comparing antibiotics to placebo for paediatric URTIs concluded 
that antibiotic treatment did not alter clinical outcome or reduce 
lowgrade fever, malaise,
myalgia, anorexia
persists up to 10 days in 35%.
mucopurulent secretions
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complication rates.23 The authors do, however, make the point that the 
efficacy of antibiotic treatment may be greater in a subgroup with a 
higher baseline risk of developing complications.
Complementary and alternative medicine (CAM) for URTI
There is growing interest in the use of complementary and alternative 
medicines for URTIs. Herbal remedies have been studied and 
conflicting results found. Two of the most commonly used and studied 
herbs are Echinacea and Andrographis paniculata, both of which are 
believed to be immunostimulants. Propolis (bee resin) has also been 
studied and stimulates antibody production.24 A major problem with the 
investigation and use of herbal products is the lack of standardisation.25
A recent meta-analysis by Shah et al found that Echinacea decreased 
the odds of developing the common cold by 58% and the duration 
of a cold by 1.4 days.26 At least two of the fourteen studies reviewed 
included children. The authors call for large randomised trials using 
standardised preparations and measuring well-defined endpoints. 
There is still insufficient data on safety, especially with prolonged use. 
The effects on blood pressure and rate-corrected QT interval are not 
known. As Echinacea inhibits cytochrome P450 3A4 enzymes, there is 
considerable potential for drug interaction. Rash, including anaphylaxis, 
has also been reported.27,28 
A review of safety and efficacy of six CAM studies for prevention and 
treatment of URTIs in children found that Echinacea did not reduce 
the duration and severity of URTIs, but that both Echinacea and 
Andrographis paniculata decreased nasal secretions. Echinacea was 
associated with a higher frequency of rash compared with placebo 
(p = 0.008). This review also found that a combination of these herbs 
with propolis and ascorbic acid reduced the number of URTI episodes, 
duration of symptoms and the number of days of illness. The review 
concludes, however, that data are inadequate to support CAM use for 
the prevention or treatment of URTIs in children.29 The impact of herbal 
immunostimulants on the immature immune system is unknown.
Other practical interventions
Saline nasal spray may be beneficial. For example, in a study of 
Swedish military recruits, daily spraying with physiological saline 
significantly reduced the incidence of the common cold and nasal 
symptoms.30 In a recent study of children with URTIs, daily nasal wash 
with a sea water-based preparation significantly reduced symptoms 
in comparison to standard medications.31 Regrettably, the study agent 
was not compared to physiological saline.
Although zinc supplementation is ineffective for treatment of URTIs,32 
iron supplementation is remarkably effective in areas where iron 
deficiency is endemic and easy to implement.33 
Honey is superior to both dextromethorphan and no treatment for 
night-time coughing associated with URTIs.34  Although the authors 
hypothesise that the effect could be due to its anti-oxidant or 
antimicrobial effects, another hypothesis is that a sweet taste might 
induce endogenous opioids.35 Honey should not be given to infants 
under 12 months of age, however, because of a real danger of infant 
botulism.36 
The promotion of hand washing in households significantly reduces the 
incidence of both respiratory and gastrointestinal infections in children 
from both impoverished and well-resourced communities.8,37
Parental smoking exacerbates respiratory infections in children and 
predisposes to asthma.38 Tobacco is a highly addictive substance and 




The influenza A, B and C are double-stranded RNA orthomyxoviruses; 
A and B are usually responsible for influenza outbreaks in humans. 
The influenza viruses are classified according to haemagglutinin (HA) 
protein and neuraminidase (NA) proteins.
Symptoms
Fever is the most common sign and is higher and of longer duration 
than in rhinovirus infection.41 Rhinorrhoea occurs commonly. The 
classic symptoms are sudden onset of fever, with or without chills, 
headache, malaise, and cough. Older children may complain of 
myalgia. The upper respiratory symptoms usually have a later 
onset and include conjunctivitis, otitis media, and gastrointestinal 
symptoms. Influenza can lead to serious sequelae such as pneumonia, 
encephalopathy or encephalitis, myocarditis, and secondary bacterial 
infections. 
Epidemiology
Patients are infectious for 24 hours prior to symptoms, and 
continue to be for about one week, or longer in young children or 
immunocompromised hosts. Children under four years of age and 
those older with bronchopulmonary dysplasia, asthma, cardiac 
abnormalities, cystic fibrosis, malignancy, diabetes, chronic renal failure 
and HIV are at risk for complications. 
Both influenza A and B viruses cause epidemics almost annually in 
many parts of the world. Community outbreaks usually affect school 
children first. These epidemics are due to antigenic drift. 
Diagnosis
Rapid diagnostic tests are becoming more available and can be very 
useful in determining whether influenza is circulating in the community 
and also in individual patients.42 Rapid tests are helpful in decision 
making with regard to antibiotics.43,44
Treatment and prevention
The adamantanes (amantadine and rimantadine) M2 ion channel 
blockers are only effective against influenza A, and therefore of no use 
unless influenza A has been identified. Two neuraminidase inhibitors 
(oseltamivir [oral] and zanamivir [inhaled]) are active against influenza 
A and B.45 If taken within 48 hours of onset, the duration of the disease 
and complications are reduced. They are also useful for post-exposure 
prophylaxis during outbreaks. Both drugs are licensed in South Africa 
for children older than one year of age. A presumptive diagnosis can 
be made in adults during epidemics or after close contact with a known 
case. Adults with an influenza-like illness with cough and fever in the 
first 48 hours are likely to have influenza.46 Children at risk for serious 
disease exposed to adults with the typical symptom complex may 
benefit from prophylaxis during winter outbreaks. 
As bacterial infections can complicate influenza, practitioners should 
have a low threshold for use of antibiotics if complications are 
suspected.
Influenza is vaccine-preventable. Licensed vaccines include the live, 
attenuated influenza vaccine (LAIV), and the trivalent inactivated 
vaccine (TIV). Only the TIV is available in South Africa. Both are 
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adapted every year for the recommended strains. The vaccines contain 
one influenza A (H3N2) and one (H1N1) virus, and also one influenza 
B virus. 
Individuals at high risk for influenza complications should be 
vaccinated.40 Additionally, people of any age with chronic underlying 
medical conditions, including HIV, should be immunised. The Centers 
for Disease Control and Prevention recommends that all children six 
months to eight years of age receive two doses of TIV separated by 
≥ 4 weeks if they have not been vaccinated previously. Children who 
receive two doses in their first vaccination year can get a single annual 
dose in subsequent years. If they only received one dose in their first 
year of vaccination, they need two doses the following year, with single 
annual doses in subsequent years. Vaccination should be encouraged, 
particularly if there are high-risk people in the home. 
Management of pharyngitis – syndromic or targeted
The two most important causes of pharyngitis requiring antibiotics 
are diphtheria and Streptococcus pyogenes. Fortunately diphtheria is 
extremely rare but can occur where public immunisation programmes 
have waned. 
Pharyngitis due to S pyogenes may be easy to recognise, as it 
manifests as a febrile, purulent pharyngitis without rhinitis or cough. 
However, milder cases can be confused with viral URTI. The most 
important consequence of not treating pharyngitis is rheumatic fever, 
which can occur in all settings, but is far more common in resource-
poor communities.47–49
There are two approaches to managing pharyngitis. In the USA 
the emphasis is on limiting antibiotics to those with bacteriological 
confirmation. A streptococcal antigen test, which gives a rapid answer 
and is highly specific, is followed by a culture, in the event of a negative 
antigen test.50
In the resource-limited primary healthcare settings where both 
laboratory tests and follow-up are unreliable, it is more appropriate 
to use a syndromic approach. In Costa Rica a single-dose of 
intramuscular benzathine penicillin for all infants and children with 
pharyngitis has been used very effectively since the 1970s to reduce 
the incidence of acute rheumatic fever from 90 to 1 per 100 000.51 
Any patient presenting with fever or a sore throat who had halitosis, 
red throat, and tonsillar hypertrophy with a white exudate was treated. 
Over a 20-year period, Streptococcus pneumoniae remained fully 
susceptible to penicillin. This represents a major success in reducing 
the lifetime disease burden of rheumatic heart disease. 
Pertussis
In infants and young children, the catarrhal stage of pertussis typically 
presents as a “common cold”. Complications are most severe in 
infants under six months of age, especially if preterm or unimmunised. 
Therefore, a “common cold” presenting in this age group should raise 
suspicion of pertussis. Infants are especially at risk until all three 
primary doses of vaccine have been given at 6, 10 and 14 weeks. 
Adolescents and adults are susceptible to pertussis due to waning 
immunity. A useful clinical case definition for adults is an acute cough 
illness lasting at least seven days, especially if associated with 
posttussive vomiting or gagging beyond two weeks.52 Any infant with 
URTI symptoms and in contact with an adult or adolescent fulfilling the 
case definition of pertussis should receive a macrolide antibiotic.
As pertussis remains a formidable disease with high morbidity and 
significant mortality in young infants, current recommendations still 
urge practitioners to consider pertussis in young infants and to give 
antibiotic prophylaxis to household contacts.53
Azithromycin is now recommended for infants below a month of 
age at a dosage of 10 mg/kg/day for five days because of the risk of 
hypertrophic pyloric stenosis with erythromycin in neonates. However, 
erythromycin at a dosage of 50 mg/kg/day for 14 days can still be 
used. For older infants and adults, clarithromycin can also be used.54
Conclusions
Knowledge of the natural history of rhinovirus infection and awareness 
of influenza, pertussis and S. pyogenes will help the clinician to make 
clinically relevant decisions. There is already a large body of evidence-
based practical information that can easily be applied to diagnosis, 
management and prevention.   
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